Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

23.5%

4 terminated/withdrawn out of 17 trials

Success Rate

76.5%

-10.0% vs industry average

Late-Stage Pipeline

35%

6 trials in Phase 3/4

Results Transparency

69%

9 of 13 completed trials have results

Key Signals

9 with results

Enrollment Performance

Analytics

Phase 2

6(35.3%)

Phase 3

6(35.3%)

Phase 1

5(29.4%)

17Total

Phase 2(6)

Phase 3(6)

Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials

NCT00983814Phase 2Completed

Study of Droxidopa Treatment in Adults With Attention Deficit Hyperactivity Disorder With Co-administration of Carbidopa

Role: lead

NCT01323374Phase 2Completed

Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With Fibromyalgia

Role: lead

NCT01132326Phase 3Completed

Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304)

Role: lead

NCT01927055Phase 3Terminated

A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy

Role: lead

NCT00657046Phase 2Completed

Safety and Benefit Study of Droxidopa to Treat Patients With Intradialytic Hypotension

Role: lead

NCT00977171Phase 2Terminated

Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome

Role: lead

NCT01176240Phase 3Completed

A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease

Role: lead

NCT00633880Phase 3Completed

Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

Role: lead

NCT00738062Phase 3Completed

Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)

Role: lead

NCT00782340Phase 3Completed

A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa

Role: lead

NCT01354158Phase 1Completed

A Dose Titration of Droxidopa in Patients With Spinal Cord Injury

Role: collaborator

NCT01116141Phase 2Completed

A Study of CH-4051 in Patients With Rheumatoid Arthritis (RA)

Role: lead

NCT00658047Phase 2Completed

A Study to Assess CH1504 in Patients With Active Rheumatoid Arthritis

Role: lead

NCT01468259Phase 1Withdrawn

A Multi-Center, Open-Label Study

Role: lead

NCT01331122Phase 1Withdrawn

Study to Assess Droxidopa in the Treatment of Freezing Of Gait Symptoms in Patients With Parkinson's Disease

Role: lead

NCT01149629Phase 1Completed

Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa

Role: lead

NCT01327066Phase 1Completed

Electrocardiographic (ECG) Safety Study of Droxidopa at Clinical and Supratherapeutic Dose

Role: lead

All 17 trials loaded